Medical device maker Abiomed (NASDAQ:ABMD) reported great results for the second quarter of fiscal 2013 today, but despite strong revenue growth, the stock took a massive 30% plunge.

In the following video, health care analysts Max Macaluso and David Williamson discuss Abiomed's earnings report and the reasons behind today's dramatic decline.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.